The Efficacy Of Ranibizumab In The Treatment Of Macular Edema Second

Retinal vein occlusion ( RVO ) causes significant visual loss in patients with medical diseases especially systemic hypertension. Centrally involving macular edema is the main cause of loss of vision in such patients. previous treatment strategies for macular edema involve argon laser retinal photocoagulation, Radial optic neurotomy, intravitreal injections of steroids but recently the introduction of anti-vascular endothelial growth factor medications represents a breakthrough and has revolutionized the treatment of retinal vein occlusion associated macular edema in addition to the beneficial effect of suppressing the risky retinal neovascularization. Ranibizumab ( Lucentis ) is one of the most commonly used Anti-VEGF drugs in treatment of macular edema associated with retinal vein occlusion RVO whether the central type ( CRVO ) or the branch type ( BRVO ).

The research book was to evaluate the efficacy of ranibizumab (Lucentis) injection in treating patients with CRVO & BRVO induced macular edemaand to compare its efficacy in ischemic versus perfused forms of RVO.RVO: Retinal Vein occlusion.CRVO: Central Retinal Vein occlusion.BRVO: Branch Retinal Vein occlusion.